Recent News

• 09.11.2025 - Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
• 09.03.2025 - Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
• 09.02.2025 - Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 07.16.2025 - Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
• 07.15.2025 - Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
• 06.03.2025 - Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Recent Filings

• 09.11.2025 - EX-99.1 EX-99.1
• 09.11.2025 - 8-K Current report
• 09.03.2025 - 8-K Current report
• 09.03.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.28.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 07.15.2025 - 8-K Current report
• 07.15.2025 - EX-99.1 EX-99.1